Genetics News

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation. MiniVec™ was developed to remove constraints that have historically limited plasmid safety, scalability, and regulatory acceptance. By minimizing ba...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--SCIEX highlights six industry collaborations as it continues to build an integrated software environment with SCIEX software solutions....

FOSTER CITY, Calif.--(BUSINESS WIRE)--GLP-1 medicines are being prescribed for weight loss at a scale the healthcare system has never managed before. Clinicians can measure weight loss. What they still cannot see, in any scalable, non-invasive way, is which patients are biologically positioned to respond before treatment begins, or how therapy is changing disease biology once it starts. Hepta today announced data at Digestive Disease Week 2026 showing that a blood-based assay analyzing cell-fre...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera to Present Non-Viral RIPPLE™ Platform Data Demonstrating Multi-Tissue Delivery and Gene Expression at ASGCT 2026...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform that enables expansion into in vivo rejuvenation and reprogramming, today announced the appointment of Stefan Irion, MD, as chief scientific officer. Dr. Irion brings more than two decades of experience translating stem cell science into clinical...

PRINCETON, N.J.--(BUSINESS WIRE)--Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2...

SAN FRANCISCO & COLUMBUS, Ohio--(BUSINESS WIRE)--Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to support the development and manufacturing of EPI-321, Epicrispr’s investigational AAV gene therapy for facioscapulohumeral muscular dystrophy (FSHD). Through this collaboration...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h...

DURHAM, N.C. and SEATTLE--(BUSINESS WIRE)--As momentum builds around next-generation approaches to treat chronic hepatitis B (HBV), Tune Therapeutics, a leading epigenome editing company, will spotlight new clinical data at the European Association for the Study of the Liver (EASL) Congress 2026 that underscore the promise of its approach and potential to unlock a finite therapy. At the meeting, Dr. Ed Gane, Professor of Medicine at the University of Auckland and a globally recognized authority...